Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma

Lijun Xu¹, Qing Zheng¹* and Wenwen Liu²*

Abstract

Background: The induction of ferroptosis and pyroptosis has been highlighted as a novel approach to decide cancer cell fate. However, few studies have systematically explored the role of combining these two novel cell death modalities in hepatocellular carcinoma (HCC).

Methods: Ferroptosis-related genes (FRGs) and pyroptosis-related genes (PRGs) were retrieved and downloaded from FerrDb and GeneCards database, respectively. A prognostic classifier integrating with prognostic differentially expressed FRGs and PRGs was constructed by the least absolute shrinkage and selection operator (LASSO) algorithm in the TCGA-LIHC dataset and verified using the ICGC (LIRI-JP) dataset.

Results: A total of 194 differentially expressed FRGs and PRGs were identified and named as differentially expressed genes (DEGs) and, out of them 79 were found dramatically correlated with prognosis in HCC. Based on 13 key DEGs with prognostic value, a novel expression signature was constructed and used to stratify HCC patients into 2 groups. Kaplan–Meier analysis demonstrated that high-risk patients had a more dismal prognosis. Receiver operating characteristic curve (ROC) and multivariate Cox analysis confirmed its predictive power and independent characteristic. Immune profile analysis demonstrated that high-risk group had prominent upregulation of immunosuppressive cells, including macrophages, Th2 cells and Treg. The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4+/PD-1-, CTLA4-/PD-1+. © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Hepatocellular carcinoma (HCC) is a prevalent malignancy worldwide which is characterized by increasing incidence and unfavorable prognosis [1, 2]. Although early-stage HCC patients could receive liver resection, transplantation and radiofrequency ablation, many patients still suffer from tumor recurrence [3]. As a novel therapeutic approach, immunotherapies based on immune checkpoint inhibitors (ICIs) have benefited HCC patients in many clinical trials [4]. For unresectable HCC patients, the therapeutic efficacy of atezolizumab plus bevacizumab for overall survival (OS) is superior to that of sorafenib [5]. However, some HCC patients who receive ICIs treatment, such as nivolumab and pembrolizumab fail to show significant improvement in OS [6, 7], which might be due to tumors’ innate resistance to apoptosis [8]. Thus, inducing novel modalities of cell death has become a promising target of antitumor therapeutic strategy. Ferroptosis and pyroptosis are such essential biological processes in HCC [9–11].

As an iron-dependent type of regulated cell death, ferroptosis is characterized by accumulation of lipid peroxidation to lethal levels [12]. Currently, genes identified to regulate this novel form of cell death could be classified into 3 categories: drivers of ferroptosis (DOF), suppressors of ferroptosis (SOF) and others, which could either drive or suppress ferroptosis based on the context [13, 14]. Pyroptosis is a lytic form of regulated cell death characterized by release of many proinflammatory mediators. There are 2 major methods by which dead cells could activate pyroptosis: GSDMD-dependent manner regulated by caspase1/4/5/11 and GSDME-dependent manner regulated by caspase 3 [15–19].

Accumulating evidence has identified the induction of ferroptosis and pyroptosis as a novel approach by which CD8+ T cells could inhibit tumor growth. For instance, CD8+ T cells could release IFN-γ to downregulate SLC7A11 expression, resulting in lipid ROS accumulation and tumor cell ferroptosis [20]. The activation of ferroptosis further promotes antitumor immunity. Besides, CD8+ T cells could release GzmA (GSDMB-cleaving enzyme) and GzmB (GSDME-cleaving enzyme) to induce pyroptosis. Induced tumor cell pyroptosis could activate IL-1β, which is derived from macrophages and required for antitumor immunity [8]. The induction of ferroptosis and pyroptosis could enhance anticancer immunity and suppress tumor growth, suggesting a favorable prognosis for HCC patients. However, few studies have systematically discussed the possibility of combining these 2 cell death modalities in HCC.

Thus, our study focuses on the comprehensive analysis of a combined ferroptosis-related genes (FRGs) and pyroptosis related genes (PRGs) for HCC with regard to prognosis, clinicopathological feature, chemotherapeutic efficacy, tumor-infiltrating immune cells and immunosuppressive molecules.

Materials and methods
Acquisition of data, FRGs and PRGs
Gene expression profiling and survival data of 365 HCC patients were obtained from The Cancer Genome Atlas liver hepatocellular carcinoma (TCGA-LIHC) dataset [21, 22]. The scale method provided by R “limma” package was used to normalize gene expression values. Another 231 HCC patients with valid RNA-seq data and survival data from the ICGC (LIRI-JP) dataset were downloaded (Table 1). Gene expression values after read count normalization were used.

Then, 173 FRGs and 120 PRGs were retrieved from the FerrDb and GeneCards website, respectively.

Generation of differentially expressed genes (DEGs) with prognostic value
DEGs between HCC samples and normal ones were identified by R “limma” package in the TCGA dataset and false discovery rate (FDR) < 0.05 was set as the threshold. Then, DEGs were subjected to univariate Cox analysis to screen out FRGs and PRGs with prognostic value and P value < 0.05 was regarded as statistical difference. Venn diagram was plotted in which the interaction between DEGs and prognosis-related genes was displayed. Correlation analysis among these prognosis-related DEGs was conducted and an interaction network was analyzed in the STRING database to identify hub genes [23].

Construction of a combined ferroptosis and pyroptosis signature and assessment of its clinical utility
The least absolute shrinkage and selection operator (LASSO) algorithm with tenfold cross-validation, which could minimize the risk of overfitting was used to shrink
and select variables [24]. Some genes with a regression coefficient of non-zero were identified as the optimal predictors for OS and incorporated into this novel signature, whose risk score was calculated according to the normalized gene expression value and its corresponding regression coefficient. The median risk score was then used as the cutoff value to divide HCC patients into 2 groups. The difference of clinicopathological features between high- and low-risk group was analyzed by Wilcoxon signed-rank test. The relationship between clinicopathological parameters and risk score was investigated by Chi-square test.

Estimation of chemotherapeutic efficacy, ICis-related molecules and Immunophenoscore (IPS) with this signature

To assess whether this signature was associated with the half inhibitory concentration IC50 of common antitumor drugs and chemotherapeutic efficacy, we applied “pRRophetic” package in R. By constructing the ridge regression model based on Genomics of Drug Sensitivity in Cancer (GDSC) (www.canerrxgene.org/) cell line expression spectrum and TCGA gene expression profiles, the package could apply pRRophetic algorithm to predict drug IC50. Wilcoxon signed-rank test was implemented to compare the difference of IC50 between different risk groups. To investigate the relationship between this combined ferroptosis and pyroptosis signature and immunosuppressive molecules, we explored the difference of CTLA4, HAVCR2, LAG3, PDCD1 and TIGIT expression between high- and low-risk group using R “limma” package and applied “ggpubr” package to transform the results into a visual violin plot. As a superior biomarker to predict response of anti-PD-1 and CTLA-4 therapies, IPS could calculate the determinants of tumor immunogenicity and depict the cancer antigenomes and intratumoral immune profiles. This scoring scheme derived from a panel of immune-related genes, which belong to four classes: suppressor cells, effector cells, immunomodulators or checkpoints, and MHC-related molecules. By averaging the samplewise Z scores of the four classes within the respective category, the sum of the weighted averaged Z score was calculated as the IPS.

Validation of this combined ferroptosis and pyroptosis related signature

The Kaplan–Meier analysis was conducted to analyze the difference of OS between risk groups. R software was used to visualize the distribution of risk score and survival outcome of each HCC patient. R “timeROC” package was used to calculate area under the curve (AUC) of 1-, 2-, 3-year receiver operating characteristic curve (ROC) to evaluate the predictive ability of this novel signature. Principal component analysis (PCA) and t-SNE analysis were conducted to explore whether this signature could differentiate HCC patients between different risk groups. Uni- and multi variate Cox analyses were

| Table 1 Baseline characteristics of HCC patients involved in this research |
|-----------------------------|-----------------------------|-----------------------------|
| Characteristics             | TCGA-LIHC dataset (N = 365) | ICGC-LINCP-JP dataset (N = 231) |
| Age                         |                             |                             |
| ≤ 60                       | 173 (47.4)                  | 49 (21.2%)                  |
| > 60                       | 192 (52.6)                  | 182 (78.8%)                 |
| Gender                      |                             |                             |
| Male                       | 246 (67.4%)                 | 170 (73.6%)                 |
| Female                     | 119 (32.6)                  | 61 (26.4%)                  |
| Grade                       |                             |                             |
| G1-2                       | 230 (63.0%)                 | NA                          |
| G3-4                       | 130 (35.6%)                 | NA                          |
| Unknown                    | 5 (1.4%)                    | NA                          |
| T stage                    |                             |                             |
| T1-2                       | 271 (74.2%)                 | NA                          |
| T3-4                       | 91 (24.9%)                  | NA                          |
| Unknown                    | 3 (0.8%)                    | NA                          |
| N stage                    |                             |                             |
| N0                         | 248 (67.9%)                 | NA                          |
| N1                         | 4 (1.1%)                    | NA                          |
| Unknown                    | 113 (31.0%)                 | NA                          |
| M stage                    |                             |                             |
| M0                         | 263 (72.1%)                 | NA                          |
| M1                         | 3 (0.8%)                    | NA                          |
| Unknown                    | 99 (27.1%)                  | NA                          |
| Stage                      |                             |                             |
| Stage I-II                 | 254 (69.6%)                 | 141 (61.0%)                 |
| Stage III-IV               | 87 (23.8%)                  | 90 (39.0%)                  |
| Unknown                    | 24 (6.6%)                   | 0 (0%)                      |
| Child_Pugh class           |                             |                             |
| A                          | 216 (59.2%)                 | NA                          |
| B                          | 21 (5.8%)                   | NA                          |
| C                          | 1 (0.2%)                    | NA                          |
| Unknown                    | 127 (34.8%)                 | NA                          |
| Cirrhosis                  |                             |                             |
| No                         | 132 (36.2%)                 | NA                          |
| Yes                        | 77 (21.1%)                  | NA                          |
| Unknown                    | 156 (42.7%)                 | NA                          |
| Survival status            |                             |                             |
| Alive                      | 235 (64.4%)                 | 189 (81.8%)                 |
| Deceased                   | 130 (35.6%)                 | 42 (18.2%)                  |

HCC hepatocellular carcinoma, TCGA The Cancer Genome Atlas, LIHC liver hepatocellular carcinoma, ICGC International Cancer Genome Consortium
conducted to confirm whether this signature could serve as an independent predictor for HCC prognosis.

Functional enrichment analysis and immune profile analysis
DEGs between different risk groups were screened out by R “limma” package and we set FDR < 0.05 and \( |\log_2\text{fold change}| > 1 \) as the threshold. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis [25–27] were then performed to understand the biological function and pathways of these DEGs by using “clusterProfiler” R package. To explore the immune infiltration profiles between different risk groups, we conducted single-sample gene set enrichment analysis (ssGSEA) to calculate the score of 16 immune-cell features and 13 immune-function characteristics [28].

Results
Identification of prognostic DEGs
A total of 194 DEGs between 374 HCC samples and 50 normal ones were screened out and out of them 79 were identified associated with OS in the univariate Cox analysis (Fig. 1). The protein–protein interaction (PPI) network among these prognostic DEGs were presented in Fig. 2a, in which there were 79 nodes and 230 edges. Genes with the top 15 degree of interaction were identified as hub genes (Fig. 2b). The correlation among 79 prognostic DEGs was displayed in Fig. 2c.

Construction of a combined ferroptosis and pyroptosis signature
Based on the expression profiles of 79 prognostic DEGs mentioned above, we conducted LASSO regression analysis to develop a novel signature, in which a total of 13 genes were identified as the optimal variables. Among them ATG3, FTL3, G6PD, HILPDA, NRAS, PRDX6, SLC1A5, SLC7A11 were FRGs, SQSTM1 participated in both ferroptosis and pyroptosis, and the remaining 4 genes (GLMN, LRPPRC, MKI67, UBE2D2) were PRGs. The risk score for this novel signature was: [ATG3 expression * (0.0599818988151381)] + [FTL3 expression * (-0.321132320389413)] + [G6PD expression * (0.0881814324303116)] + [GLMN expression * (0.130781902193193)] + [HILPDA expression * (0.119282064768739)] + [LRPPRC expression * (0.00792886569542188)] + [MKI67 expression * (0.0165502840606549)] + [NRAS expression * (0.0916391974243284)] + [PRDX6 expression * (0.114398632925529)] + [SLC1A5 expression * (0.05212150097305)] + [SLC7A11 expression * (0.0940765304518399)] + [UBE2D2 expression * (0.04686256927426)]. The median risk score was then used as the cutoff value to stratify HCC samples into 2 groups, in which there were 182 high- and 183 low-risk cases in the TCGA dataset.

Evaluation of the clinical utility of this novel signature
Kaplan–Meier analysis indicated that high-risk group had a more dismal OS (Fig. 3a, P < 0.001). Consistently, as was shown in Fig. 3b, low-risk patients had a lower probability to suffer from earlier death compared with those high-risk counterparts. PCA and t-SNE analysis demonstrated that HCC samples in different risk groups were easily distinguished (Fig. 3c and d). Uni- and multi-variate Cox analyses confirmed that this signature could predict prognosis independent of clinicopathological parameters (Fig. 3e and f). The AUC of 1-, 2-, 3-year ROC for this signature was 0.811, 0.743 and 0.721 (Fig. 3g) and the AUC of this signature was higher than that of clinicopathological indicators (Fig. 3h). Besides, Wilcoxon signed rank test and Chi-square test showed that clinicopathological features (Fig. 4a), including tumor grade (Fig. 4b), clinical stage (Fig. 4c) and T stage (Fig. 4d) were different between risk groups.

Exploration of the relationship between this signature and chemotherapeutic efficacy, immunosuppressive molecules and IPS
By evaluating the role of this signature in predicting the efficacy of common chemotherapeutics, immunosuppressive molecules and IPS, we discovered that low-risk group had a higher IC50 of cisplatin, mitomycin and doxorubicin (Fig. 5a) and was negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT (Fig. 5b) and ICIs treatment represented by CTLA4-/PD-1-, CTLA4+/PD-1-, CTLA4-/PD-1+ (Fig. 5c).

Verification of this combined ferroptosis and pyroptosis signature and construction of a nomogram
To assess the predictive ability of this novel signature, ICGC dataset was used as external validation. By calculating the risk score of each HCC sample based on the same formula derived from TCGA dataset, we stratified them into high- or low- risk group according to the cutoff median value (Fig. 6a). Patients with low risk were less susceptible to earlier death and had favorable OS by comparison with those high-risk counterparts (Fig. 6b and c). The AUC of 1-, 2-, 3-year ROC for this signature in the ICGC dataset was 0.750, 0.728 and 0.715 (Fig. 6d). PCA and t-SNE analysis demonstrated that high- and low-risk HCC samples were scattered in two directions (Fig. 6e and f). Uni- and multi-variate Cox analysis confirmed that this signature could predict OS
Fig. 1 Identification of DEGs with prognostic value in the TCGA-LIHC dataset. a. The Venn diagram presented DEGs associated with OS in the univariate Cox regression analysis. b. The heatmap showing 79 prognostic DEGs. c. The forest plot displayed the relationship between 79 prognostic DEGs and OS in the univariate Cox regression analysis.
Fig. 2  PPI network and correlation analysis of 79 prognostic DEGs. a The PPI network among candidate genes obtained from the STRING database. b Hub genes with the top 15 degree of interaction. c The correlation analysis of candidate genes.
Fig. 3  Construction of a combined ferroptosis and pyroptosis signature in the TCGA-LIHC dataset.  

a The Kaplan–Meier curve survival analysis.  
b The risk score curve plot and scatter plot of high- and low-risk HCC patients.  
c PCA plot of the TCGA dataset.  
d t-SNE analysis of the TCGA dataset.  
e Univariate Cox analysis of OS in the TCGA dataset.  
f Multivariate Cox analysis of OS in the TCGA dataset.  
g AUC of 1, 2, 3-year ROC used to assess the predictive ability of this signature.  
h AUC of this signature and clinicopathological parameters
Fig. 4 The relationship between clinicopathological features of this novel signature Clinical characteristics (a), including tumor grade (b), clinical stage (c) and T stage (d) were significantly associated with the risk and risk score.
Fig. 5 The relationship between this signature and chemotherapeutic efficacy and ICIs-related molecules. **a** Low-risk group had a higher IC50 of cisplatin, doxorubicin and mitomycin. **b** High-risk group was positively related with CTLA4, HAVCR2, LAG3, PDCD1 and TIGIT. **c** Low-risk group was negatively related with ICIs treatment represented by CTLA4-/PD-1-, CTLA4+/PD-1-, CTLA4+/PD-1+.
Fig. 6 Validation of this novel signature in the ICGC (LIRI-JP) dataset. 

- **a** The risk score curve plot in the ICGC dataset. 
- **b** The risk score scatter plot of high- and low-risk HCC patients. 
- **c** The Kaplan–Meier curve survival analysis. 
- **d** AUC of 1-, 2-, 3-year ROC used to assess performance of this signature in predictive ability in the ICGC dataset. 
- **e** PCA plot of the ICGC dataset. 
- **f** t-SNE analysis of the ICGC dataset. 
- **g** Univariate Cox analysis of OS in the ICGC dataset. 
- **h** Multivariate Cox analysis of OS in the ICGC dataset.
independent of clinicopathological parameters (Fig. 6g and h). To provide a quantitative approach by which clinicians could predict probability of survival in HCC patients, we developed a nomogram by integrating of this novel prognostic signature and clinicopathological characteristics, including age, albumin, total bilirubin, prothrombin time, Child_Pugh classification, histologic grade, TNM stage and liver cirrhosis (Fig. 7a). The predictive accuracy of this nomogram was validated by its discrimination and calibration performance (Fig. 7b and c).

Functional analysis and immune cell infiltration
To explore the biological function and pathways associated with this signature, we performed GO and KEGG analysis based on DEGs between high- and low-risk group. In both TCGA and ICGC dataset, GO terms for biological process were organelle fission, nuclear division and sister chromatid segregation; for cellular component were mainly associated with chromosome, such as spindle, condensed chromosome, centromeric region (Fig. 8a and b). Besides, the KEGG results revealed that these DEGs mainly participated in cell cycle, PI3K-Akt signaling pathway and cellular senescence (Fig. 8c and d).

To further investigate the relationship between this signature and immune profiles, we performed ssGSEA to calculate the score of immune-cell features and immune-function characteristics. The score of macrophages, Th2_cells and Treg was higher in high-risk group, while neutrophils and NK cells earned a higher score in low-risk group (Fig. 9a and b). Besides, MHC_class_I and Type_II_Ifn_response was mainly enriched in high- and low-risk group, respectively (Fig. 9c and d).

Discussion
As two novel cell death modalities, mounting evidence has demonstrated that ferroptosis and pyroptosis are intimately related with tumor progression [29–31]. However, few studies have thoroughly explored the role of combing these 2 novel cell death modalities in HCC. In the present research, we systematically investigated the expression and prognostic significance of 173 FRGs and 120 PRGs in HCC. To our surprise, most of the FRGs (75.2%) and PRGs (59.2%) were found differentially expressed between HCC samples and normal ones, and approximately 40% of them were associated with survival in the univariate Cox analysis. These findings significantly demonstrated the potential role of ferroptosis and pyroptosis in HCC and the possibility of constructing a prognostic expression signature from the perspective of these 2 cell death modalities.

A total of 13 genes were finally incorporated into this novel signature. ATG3, a major autophagy regulator, could promote ferroptosis via degradation of ferritin and accumulation of iron [32]. FLT3 inhibitor could prevent lipid peroxidation to protect cells against oxidative glutamate toxicity, which involves 3 cell death modalities: apoptosis, ferroptosis and necroptosis [33]. G6PD has been considered as a critical pacesetter of pentose phosphate pathway that prevents erastin-induced ferroptosis when it was knocked down [12]. HIF-2a-HILPDA could selectively enrich polyunsaturated fatty acids and acts as a central driver of a ferroptotic cell death [34]. In HL-60/ NRASQ61L cells, HMGB1 knockdown could decrease erastin-induced ferroptosis via RAS-JNK/p38 signaling [35]. PRDX6, an essential family member of nonseleminon peroxidases, could protect cells against ferroptotic process and serve as a potential target to enhance antitumor activity of ferroptosis-based chemotherapeutics [36]. SLC1A5, which mediates uptake of neutral amino acids, has been reported to cause ferroptotic cell death when it is suppressed by miR-137 [37]. SLC7A11 is a mechanistic determinant which promotes tumoral lipid oxidation and ferroptosis when it is synergistically suppressed by immunotherapy and radiotherapy [10]. SQSTM1 is passively released in the context of GSDMD-mediated pyroptosis and found to mediate various biological processes, especially autophagy and ferroptosis [38, 39]. Downregulation of GLMN levels could activate inflammasome and pyroptotic cell death of macrophages [40]. Tetherin could prevent T cell pyroptosis by interacting with LRPPRC and preventing the formation of LRPPRC-Bcl-2-Beclin 1 ternary complex [41]. MKI67, a well-known marker of proliferation, was found involved in caspase-3-mediated apoptosis and caspase-1-mediated pyroptosis of CD4 T cells in HIV [42]. Knockdown of UBE2D2, a member of ubiquitin-conjugating enzymes, could significantly reduce SQSTM1 recruitment, which is passively released in the context of GSDMD-mediated pyroptosis [43].

Recent studies have confirmed that ferroptosis and pyroptosis are significantly associated with antitumor activity. Tumor cells undergoing ferroptosis and pyroptosis could recruit tumor-suppressed immune cells and enhance antitumor immunity. To investigate the immune-cell characteristics and immune-function features of this signature, we performed ssGSEA based on DEGs between different risk groups. The results showed that high-risk group of both datasets earned higher scores of macrophages, Th2_cells and Treg, which are thought to promote tumor growth and invasion and tightly associated with dismal prognosis [44–47]. MHC_class_I, a major antigen presenting process, was also enriched in high-risk group. It is possibly because the pore formation with the pyroptotic cellular plasma membrane could release immune stimulants, which could attract activated dendritic cells and thus, promote anti-tumor...
Fig. 7 Construction of a nomogram for predicting survival outcome. 

a Nomogram integrating of this novel ferroptosis and pyroptosis-related gene signature and clinicopathological features. 

b AUC of time-dependent ROC curves for nomogram. 

c Calibration plot of nomogram.
Fig. 8  Representative results of GO and KEGG analyses. The most significant GO enrichment and KEGG pathways in the TCGA dataset (a, c) and ICGC dataset (b, d) were displayed.
Fig. 9 Comparison of the ssGSEA score between different risk groups in the TCGA dataset and ICGC dataset. The score of 16 immune cells (a, b) and 13 immune-related functions and pathways (c, d) were displayed in boxplots. Adjusted P values were showed as: ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001
T cell activity [48]. Besides, cells undergoing ferroptosis could attract dendritic cells by releasing lipid mediators [49]. The scores of NK cells and Type II IFN_Response were higher in low-risk group by the fact that type II IFN is mainly released by NK cells [50], which are major components of immune defense against tumorigenesis [51].

Several shortcomings should be acknowledged in our study. First, this combined ferroptosis and pyroptosis signature was constructed and verified using public data-set. Real-world dataset is required to assess its accuracy and efficacy. Second, the molecular mechanisms between genes identified by this signature and tumor immunity in HCC are not elucidated. Future experimental studies are needed to address this problem.

Conclusions
In conclusion, a combined ferroptosis and pyroptosis signature was constructed for HCC, which was tightly associated with prognosis, clinicopathological features, immune profiles, chemotherapeutic efficacy and immunosuppressive molecules. The molecular mechanisms between this signature and tumor immunity are largely unknown and require further experimental investigation.

Abbreviations
HCC: Hepatocellular carcinoma; ICIs: Immune checkpoint inhibitors; OS: Overall survival; DOF: Drivers of ferroptosis; SOF: Suppressors of ferroptosis; FRGs: Ferroptosis-related genes; PRGs: Pyroptosis-related genes; DEGs: Differentially expressed genes; FDR: False discovery rate; LASSO: The least absolute shrinkage and selection operator; IC50: The half inhibitory concentration; AUC: Area under the curve; ROC: Receiver operating characteristic curve; PCA: Principal component analysis; GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; ssGSEA: Single-sample gene set enrichment analysis.

Acknowledgements
All authors thank the family for participating in the study.

Authors’ contributions
Lijun Xu performed this study and drafted the article. Qing Zheng and Wenwen Liu helped design this research and edit the manuscript. The final version of the manuscript was approved by all authors.

Funding
No sources of funding were required for this work.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in the TCGA-LIHC project (https://portal.gdc.cancer.gov/repository) and ICGC database (https://dcc.icgc.org/).

Declarations
Ethics approval and consent to participate
Investigation has been conducted in accordance with the Declaration of Helsinki and national and international guidelines. All datasets in the present research were downloaded from public databases, including TCGA and ICGC. Thus, the present study was exempted from the approval of ethics review board in Renji hospital, School of Medicine, Shanghai Jiao Tong University. The current study follows the TCGA and ICGC data access policies and publication guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 3 June 2021 Accepted: 7 February 2022
Published online: 02 March 2022

References
1. Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma [J]. Semin Diagn Pathol. 2017;34(2):153–9.
2. Kulik L, El-Seraq HB. Epidemiology and Management of Hepatocellular Carcinoma [J]. Gastroenterology. 2019;156(2):477–91.e1.
3. Tabrizian F, Jibara G, Shragar B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis [J]. Ann Surg. 2015;261(5):947–55.
4. Hilmi M, Neuzillet C, Caldeira J, et al. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions [J]. J Immunother Cancer. 2019;7(1):333.
5. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J]. N Engl J Med. 2020;382(20):1894–905.
6. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J]. J Clin Oncol. 2020;38(3):193–202.
7. Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma [J]. J Exp Clin Cancer Res. 2019;38(1):447.
8. Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity [J]. J Hematol Oncol. 2020;13(1):110.
9. Zhang Z, Zhang T, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity [J]. Nature. 2020;579(7799):415–20.
10. Lang X, Green MD, Wang W, et al. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11 [J]. Cancer Discov. 2019;9(12):1673–85.
11. Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy [J]. Nature. 2019;569(7755):270–4.
12. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death [J]. Cell. 2012;149(5):1060–72.
13. Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression [J]. Nature. 2015;520(7545):57–62.
14. Tarangelo A, Magtanong L, Bieging-Rolett KT, et al. p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells [J]. Cell Rep. 2018;22(3):569–75.
15. Agard NJ, Malby D, Wells JA. Inflammatory stimuli regulate caspase substrate profiles [J]. Mol Cell Proteomics. 2010;9(5):880–93.
16. Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling [J]. Nature. 2015;526(7575):666–71.
17. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death [J]. Nature. 2015;526(7575):660–5.
18. Crawford ED, Wells JA. Caspase substrates and cellular remodeling [J]. Annu Rev Biochem. 2011;80:1055–87.
19. Julien O, Wells JA. Caspases and their substrates [J]. Cell Metab. 2019;30(1):14–5.
20. Floquet D, Roël JP, et al. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes [J]. J Transl Med. 2021;19(1):26.
21. Liu GM, Zeng HD, Zhang CY, et al. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma [J]. Cancer Cell Int. 2019;19:138.
22. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored [J]. Nucleic Acids Res. 2011;39(Database issue):DS61-8.
24. Tibshirani R. The lasso method for variable selection in the Cox model [J]. Stat Med. 1997;16(4):385–95.
25. Kanehisa M. Toward understanding the origin and evolution of cellular organisms [J]. Protein Sci. 2019;28(11):1947–51.
26. Kanehisa M, Furumichi M, Sato Y, et al. KEGG integrating viruses and cellular organisms [J]. Nucleic Acids Res. 2021;49(D1):D545–51.
27. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes [J]. Nucleic Acids Res. 2000;28(1):27–30.
28. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity [J]. Cell. 2015;160(1–2):48–61.
29. Cui J, Zhou Z, Yang H, et al. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis [J]. Mol Cancer Res. 2019;17(6):1316–25.
30. Liu HJ, Hu HM, Li GZ, et al. Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression [J]. Front Cell Dev Biol. 2020;8:538.
31. Wu Y, Zhang S, Gong X, et al. The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression [J]. Mol Cancer. 2020;19(1):39.
32. Zhou B, Liu J, Kang R, et al. Ferroptosis is a type of autophagy-dependent cell death [J]. Semin Cancer Biol. 2020;66:89–100.
33. Kang Y, Tiziani S, Park G, et al. Cellular protection using Fiz3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity [J]. Nat Commun. 2014;5:3672.
34. Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis [J]. Nat Commun. 2019;10(1):1617.
35. Ye F, Chai W, Xie M, et al. HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS(Q61L) cells [J]. Am J Cancer Res. 2019;9(6):730–9.
36. Lu B, Chen XB, Hong YC, et al. Identification of PRDX6 as a regulator of ferroptosis [J]. Acta Pharmacol Sin. 2018;25(8):1457–72.
37. Zou B, Liu J, Kiliansky DJ, et al. Extracellular SQSTM1 as an inflammatory mediator [J]. Autophagy. 2020;16(12):2313–S.
38. Liu J, Yang M, Kang R, et al. Autophagic degradation of the circadian clock regulator promotes ferroptosis [J]. Autophagy. 2019;15(11):2033–5.
39. Suzuki S, Suzuki T, Mimuro H, et al. Shigella hijacks the golulin-claAPs-inflammasome axis to promote inflammation [J]. EMBO Rep. 2018;19(1):1–101.
40. Zou J, Li W, Miloa A, et al. The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRP PRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy [J]. J Biol Chem. 2015;290(11):7269–79.
41. DoItsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection [J]. Nature. 2014;507(7484):509–14.
42. Geisler S, Vollmer S, Golombek S, et al. The ubiquitin-conjugating enzyme USP15 overcomes tumour suppressor function by targeting the ubiquitin-conjugating enzyme USP15 [J]. Autophagy. 2020;16(12):2313–5.
43. Ye J, Li W, Sano T, et al. The role of autophagy in the development of colorectal cancer [J]. Dis Colon Rectal Surg. 2015;58(1):31–8.
44. Geisler S, Vollmer S, Golombek S, et al. The ubiquitin-conjugating enzyme USP15 overcomes tumour suppressor function by targeting the ubiquitin-conjugating enzyme USP15 [J]. Autophagy. 2020;16(12):2313–5.
45. Ye J, Li W, Sano T, et al. The role of autophagy in the development of colorectal cancer [J]. Dis Colon Rectal Surg. 2015;58(1):31–8.
46. Zhang Q, He Y, Luo N, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma [J]. Cell. 2019;179(4):1330–42.
47. Yao F, Yuan Q, Song X, et al. Ypingfeng Granule Improves Th2-Biased Immune State in Microenvironment of Hepatocellular Carcinoma through TSLP-DC-OX40L Pathway [J]. Evid Based Complement Alternat Med. 2020;2020:1263053.
48. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients [J]. Gastroenterology. 2007;132(7):2328–39.
49. Erkes DA, Cai W, Sanchez IM, et al. Mutant BRAF and MEX Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis [J]. Cancer Discov. 2020;10(2):254–69.
50. di Franco S, Turdo A, Todaro M, et al. Role of Type I and II Interferons in Colorectal Cancer and Melanoma [J]. Front Immunol. 2017;8:878.
51. Liu P, Chen L, Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy [J]. J Immunol Res. 2018;2018:1206737.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.